<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02056236</url>
  </required_header>
  <id_info>
    <org_study_id>NEF-14-18</org_study_id>
    <secondary_id>NL46296.044.13</secondary_id>
    <nct_id>NCT02056236</nct_id>
  </id_info>
  <brief_title>TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation</brief_title>
  <acronym>TELSTAR</acronym>
  <official_title>TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Twente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medisch Spectrum Twente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VieCuri Medical Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université Libre de Bruxelles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maasstad Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Twente</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the effect of medical treatment of
      electro-encephalographic status epilepticus on neurological outcome of patients with
      postanoxic encephalopathy after cardiac arrest.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Electroencephalographic status epilepticus is described in 9-35% of patients with
      postanoxic encephalopathy after cardiac arrest and is associated with case fatality rates of
      90-100%. It is unclear whether (some) electroencephalographic seizure patterns in these
      patients represent a condition which can be treated with antiepileptic drugs to improve
      outcome, or have to be regarded as an expression of severe ischemic damage, in which
      treatment with antiepileptic would be futile. Therefore, both treatment with and treatment
      without antiepileptic drugs are considered standard modalities in these patients. We aim to
      compare these standard strategies and hypothesize that aggressive and early treatment of
      electro-encephalographic status epilepticus with antiepileptic drugs improves outcome as
      compared to treatment without these drugs.

      Objective: To estimate the effect of medical treatment of electro-encephalographic status
      epilepticus on neurological outcome of patients with postanoxic encephalopathy after cardiac
      arrest

      Study design: We will perform a multicenter clinical trial with randomized treatment
      allocation, open label treatment and blinded endpoint evaluation (PROBE design). The
      intervention contrast will be aggressive medical treatment vs. no treatment of
      electroencephalographic status epilepticus, in addition to standard best medical management
      of comatose patients after cardiac arrest, including mild therapeutic hypothermia.

      Study population: The study population will consist of adult patients with postanoxic
      encephalopathy after cardiac arrest, admitted to the intensive care unit, with
      electroencephalographic status epilepticus on continuous EEG, who are eligile for inclusion
      in this trial.

      Intervention: Treatment of electroencephalographic status epilepticus will be based on
      guidelines for treatment of overt status epilepticus. The objective of this treatment will be
      to suppress all epileptiform activity in the EEG. If the electroencephalographic status
      epilepticus will return after tapering sedative treatment at 24 hours, the procedure will be
      repeated. If the status will return after 2 x 24 hours, it will be considered refractory.

      Main study parameters/endpoints: The primary outcome measure will be neurological outcome
      defined as the score on the Cerebral Performance Category (CPC) at 3 months dichotomized as
      good (CPC 1-2 = no or moderate neurological disability) and poor (CPC 3-5 = severe
      disability, coma, or death).

      Sample size: With a presumed reduction of poor outcome of 7%, from 99% - 92%, alpha of 5%,
      power of 80%, one tailed testing, and one interim analysis by an independent data safety and
      monitoring board, the objected number of inclusions is 172. With an estimation of an
      incidence of electroencephalographic status epilepticus of 20% in patients with postanoxic
      coma, the total number of patients to be monitored will be 860.

      Nature and extent of the burden and risks associated with participation: Medical treatment of
      electroencephalographic status epilepticus may modify the high risk of death. Otherwise, this
      treatment of electroencephalographic status epilepticus may lead to prolonged hospitalization
      of several days of comatose patients that otherwise would have died. The risk of an increase
      of morbidity or mortality on the longer term is considered negligible.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurological outcome</measure>
    <time_frame>three months</time_frame>
    <description>The primary outcome measure will be neurological outcome defined as the score on the Cerebral Performance Category (CPC) at 3 months dichotomized as good (CPC 1-2 = no or moderate neurological disability) and poor (CPC 3-5 = severe disability, coma, or death).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long term outcome</measure>
    <time_frame>12 months</time_frame>
    <description>Secondary outcome measures will include i) mortality; ii) the CPC score at 6 and 12 months; iii) length of stay on the ICU; iv) duration of mechanical ventilation; v) seizure recurrence within one year; vi) quality of life as measured by the Medical Outcomes Study 36-item short-form health survey (SF36), depression as measured by the Montgomery and Åsberg Depression Rating Scale (MADRS) , and cognitive functioning as measured by detailed neuropsychological examination after 12 months.
Secondary outcome measures in survivors will be collected to thoroughly assess outcome and quality of life of survivors. These outcome measures will not be collected to test between-group differences, since the estimated number of survivors is small.
Furthermore, a limited amount of data on the use of resources will be collected for analysis of cost-effectiveness, including place of residence at one year and admission in hospitals, rehabilitations centers, and nursing homes within the first year.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Cardiac Arrest</condition>
  <condition>Anoxic Encephalopathy</condition>
  <condition>Status Epilepticus</condition>
  <arm_group>
    <arm_group_label>Anti-epileptic drugs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Step 1. Lorazepam 4 mg iv (initial dosage) titrated up to a maximum of 12 mg/24 hours OR midazolam 10 mg (initial dosage) up to 60 mg/24 hours (in steps of 5 mg/5 minutes) PLUS Fenytoine bolus i.v. 15-20 mg/kg in 30 minutes, followed by 150 mg 2 dd 1, adapted based on serum levels.
Step 2. Propofol infusion with a maximum of 8 mg/kg/hour PLUS A second anti-epileptic drug in addition to fenytoin: Option 1: levetiracetam bolus 1500 mg, followed by 1000 mg 2 dd 1 intravenously or Option 2: valproic acid bolus 10-20 mg/kg in 30 min, followed by15 mg/kg/day in 2 dosages intravenously.
Step 3. Thiopental, initial dosage 12,5 mg/kg/hr for the first 6 hours followed by 5 mg/kg/hr for 6 hours. After these loading dosages treatment should be guided by the EEG pattern.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No anti-epileptic drugs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.
Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline &quot;postanoxic coma&quot; in both treatment arms. Reasons for withdrawal of treatment will be documented.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-epileptic drugs</intervention_name>
    <description>Recommendations for the treatment of status epilepticus are based on recent international guidelines for treatment of overt status epilepticus.
The objective of treatment with AED is to suppress all epileptiform activity. There is no clear proof that induction of a burst-suppression pattern is of additional value and induction of burst suppression is therefore not obligate. If the electroencephalographic status epilepticus returns after tapering sedative treatment at 24 hours, the procedure will be repeated. If the status returns after 2 x 24 hours, it will be considered refractory.
Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline &quot;postanoxic coma&quot;. Reasons for withdrawal of treatment will be documented.</description>
    <arm_group_label>Anti-epileptic drugs</arm_group_label>
    <other_name>Lorazepam</other_name>
    <other_name>Midazolam</other_name>
    <other_name>Fenytoin</other_name>
    <other_name>Propofol</other_name>
    <other_name>Levetiracetam</other_name>
    <other_name>Valproate</other_name>
    <other_name>Thiopental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No anti-epileptic drugs</intervention_name>
    <description>The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.
Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline &quot;postanoxic coma&quot;. Reasons for withdrawal of treatment will be documented.</description>
    <arm_group_label>No anti-epileptic drugs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients after cardiac arrest with suspected postanoxic encephalopathy

          -  Age 18 years or older

          -  Continuous EEG with at least eight electrodes started within 24 hours after cardiac
             arrest

          -  Electroencephalographic status epilepticus on continuous EEG

          -  Possibility to start treatment within three hours after detection of
             electroencephalographic status epilepticus.

        Exclusion Criteria:

          -  A known history of another medical condition with limited life expectancy (&lt;6 months)

          -  Any progressive brain illness, such as a brain tumor or neurodegenerative disease

          -  Pre-admission Glasgow Outcome Scale score of 3 or lower

          -  Reason other than neurological condition to withdraw treatment

          -  Follow-up impossible due to logistic reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeannette Hofmeijer, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rijnstate Hospital and University of Twente</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel van Putten, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medisch Spectrum Twente and University of Twente</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janneke Horn, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barry Ruijter, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Twente</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeannette Hofmeijer, MD PhD</last_name>
    <phone>0031-88-0058877</phone>
    <email>jhofmeijer@rijnstate.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michel van Putten, MD PhD</last_name>
    <phone>0031-53-4872810</phone>
    <email>m.j.a.m.vanputten@utwente.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Erasme - Université libre de Bruxelles</name>
      <address>
        <city>Brussels</city>
        <state>Lenniksebaan 808</state>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Taccone, MD PhD</last_name>
      <phone>0032-2 555 31 11</phone>
      <email>Fabio.Taccone@erasme.ulb.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Geert Grooteplein-Zuid 10</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Hoedemaekers, MD PhD</last_name>
      <phone>0031-24- 3611111</phone>
      <email>Astrid.Hoedemaekers@radboudumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <state>Haaksbergerstraat 55</state>
        <zip>7513 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel van Putten, MD PhD</last_name>
      <phone>0031-53-4872810</phone>
      <email>m.j.a.m.vanputten@utwente.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <state>Hanzeplein 1</state>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter van den Bergh, MD PhD</last_name>
      <phone>0031-50-3616161</phone>
      <email>w.m.van.den.bergh@umcg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <state>Koekoekslaan 1</state>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Selma Tromp, MD PhD</last_name>
      <phone>0031-88-320 30 00</phone>
      <email>s.tromp1@antoniusziekenhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Meibergdreef 9</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janneke Horn, MD PhD</last_name>
      <phone>0031-20-566 9111</phone>
      <email>j.horn@amc.uva.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VieCuri Medical Centre</name>
      <address>
        <city>Venlo</city>
        <state>Tegelseweg 210</state>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert Foudraine, MD PhD</last_name>
      <phone>0031-77-320 55 55</phone>
      <email>nfoudraine@viecuri.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <state>Wagnerlaan 55</state>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannette Hofmeijer, MD PhD</last_name>
      <phone>0031-88-0058877</phone>
      <email>jhofmeijer@rijnstate.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maasstad Hospital</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3079 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsbeth Thomeer</last_name>
      <phone>0031 10 291 1911</phone>
      <email>ThomeerE@maasstadziekenhuis.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.telstartrial.nl/en/</url>
    <description>TELSTAR trial website (English version)</description>
  </link>
  <reference>
    <citation>Ruijter BJ, van Putten MJ, Horn J, Blans MJ, Beishuizen A, van Rootselaar AF, Hofmeijer J; TELSTAR study group. Treatment of electroencephalographic status epilepticus after cardiopulmonary resuscitation (TELSTAR): study protocol for a randomized controlled trial. Trials. 2014 Nov 6;15:433. doi: 10.1186/1745-6215-15-433.</citation>
    <PMID>25377067</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2014</study_first_submitted>
  <study_first_submitted_qc>February 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2014</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Twente</investigator_affiliation>
    <investigator_full_name>Jeannette Hofmeijer</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Cardiac arrest</keyword>
  <keyword>Postanoxic encephalopathy</keyword>
  <keyword>Electroencephalographic status epilepticus</keyword>
  <keyword>EEG monitoring</keyword>
  <keyword>Anti-epileptic drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Status Epilepticus</mesh_term>
    <mesh_term>Hypoxia, Brain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Lorazepam</mesh_term>
    <mesh_term>Thiopental</mesh_term>
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

